.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Covington
Cipla
QuintilesIMS
Queensland Health
UBS
Colorcon
AstraZeneca
Mallinckrodt
Express Scripts
Deloitte

Generated: November 22, 2017

DrugPatentWatch Database Preview

Claims for Patent: 6,403,649

« Back to Dashboard

Claims for Patent: 6,403,649

Title: Non-acidic cyclopentane heptanoic acid,2-cycloalkyl or arylalkyl derivatives as therapeutic agents
Abstract:The present invention provides cydopentane heptanoic acid, 2-cycloalkyl or arylalkyl compounds, which may be substituted in the 1-position with amino, amido, ether or ester groups, e.g., a 1-OH cydopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) compound. The cydopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) compounds of the present invention are potent ocular hypotensives, and are particularly suitable for the management of glaucoma. Moreover, the cydopentane heptanoic, 2-(cycloalkyl or arylalkyl) compounds of this invention are smooth muscle relaxants with broad application in systemic hypertensive and pulmonary diseases; smooth muscle relaxants with application in gastrointestinal disease, reproduction, fertility, incontinence, shock, etc.
Inventor(s): Woodward; David F. (El Toro, CA), Andrews; Steven W. (Rancho Santa Marguerita, CA), Burk; Robert M. (Irvine, CA), Garst; Michael E. (Newport Beach, CA)
Assignee: Allergan Sales, Inc. (Irvine, CA)
Application Number:09/519,834
Patent Claims: 1. A compound, that is cyclopentane N-ethyl heptenamide-5-cis-2-(3.alpha.-hydroxy-5-phenyl-1-trans-pentenyl)-3,5-dihyd roxy, [1.sub..alpha., 2.sub..beta., 3.sub..alpha., 5.sub..alpha. ]).

2. A method of treating ocular hypertension which comprises applying to the eye an amount sufficient to treat ocular hypertension of the compound of claim 1.

3. A method of treating glaucoma which comprises applying to the eye an amount sufficient to treat glaucoma of the compound of claim 1.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Johnson and Johnson
Medtronic
US Army
Daiichi Sankyo
McKesson
AstraZeneca
Cerilliant
Merck
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot